A retrospective analysis of migraine prophylaxis with anti-CGRP monoclonal antibodies at the hospital of Lithuanian University of Health Sciences Kaunas Clinics
Background. Migraine is a primary headache disorder described by episodic attacks that can progress to chronic migraine. Preventive treatment of anti-calcitonin gene-related peptide monoclonal antibodies (anti-CGRP mAbs) is currently being widely investigated worldwide. Materials and methods. A tot...
Saved in:
Main Authors: | V. Karpavičiūtė, K. Statkevičienė, G. Žemgulytė |
---|---|
Format: | Article |
Language: | English |
Published: |
Vilnius University Press
2023-10-01
|
Series: | Neurologijos seminarai |
Subjects: | |
Online Access: | https://www.journals.vu.lt/neurologijos_seminarai/article/view/33258 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Erenumab effectiveness and safety: comparison of real-life data and clinical trial results
by: Austėja Dapkutė, et al.
Published: (2021-12-01) -
Patients’ Experiences During the Long Journey Before Initiating Migraine Prevention with a Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody (mAb)
by: Elizabeth Seng, et al.
Published: (2024-09-01) -
Real-World Experience of Erenumab in Patients with Migraine in Germany: The SPECTRE Study
by: Charly Gaul, et al.
Published: (2024-10-01) -
The Effect of Calcitonin Gene-Related Peptide Monoclonal Antibodies on Quality of Life among Migraine Patients: Pilot Study at the Hospital of Lithuanian University of Health Sciences Kaunas Clinics
by: Monika Remenčiūtė, et al.
Published: (2024-05-01) -
Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention
by: Christian Lampl, et al.
Published: (2024-12-01)